医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Discovery Collaboration Agreement With Janssen

2017年04月07日 PM08:55
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO: 4587) announced today that it has entered into a multi-target discovery and optimization collaboration with US-based Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). Under the agreement, facilitated by Johnson & Johnson Innovation, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple metabolic and cardiovascular targets of interest selected by Janssen, and to optimize hit peptides into therapeutic peptides or small molecule products. Janssen also holds an exercisable option to peptide-drug conjugate (PDC) use and applications. Janssen will have the right to develop and commercialize all compounds resulting from the collaboration. Under the terms of the agreement, PeptiDream would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.15 billion. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.

Over the past seven years, PeptiDream has established funded discovery collaborations with 16 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, and Asahi Kasei all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly, and Genentech.

[Comment from Kiichi Kubota, CEO and President of PeptiDream Inc]

Over the past few years PeptiDream has greatly expanded our ability to turn PDPS-identified peptide candidates into peptide therapeutics, small molecule drugs, and peptide drug conjugates (PDCs), and we greatly look forward to working with a world-renowned organization like Janssen to leverage these capabilities to discover and development the next generation of first-in-class and best-in-class therapeutics.”

View source version on businesswire.com: http://www.businesswire.com/news/home/20170407005264/en/

CONTACT

PeptiDream Inc.
Patrick C Reid, +81-3-5790-9991
(Tokyo)
p-reid@peptidream.com
http://www.peptidream.com/

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田呈报NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者及维持治疗的1/2期研究数据
  • Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
  • Invacare Corporation Announces Closure of China Manufacturing Facility in Line with Strategic Transformation
  • Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Bionext推出Biosight:药品研究的革命性在线平台